Expression and Malignant Potential of B4GALNT4 in Esophageal Squamous Cell Carcinoma

• Published in: Annals of surgical oncology Vol. 27; no. 9; pp. 3247 - 3256
• Main Authors: Baba, Hayato, Kanda, Mitsuro, Sato, Yusuke, Sawaki, Koichi, Shimizu, Dai, Koike, Masahiko, Motoyama, Satoru, Kodera, Yasuhiro, Fujii, Tsutomu
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2020; Springer Nature B.V
• Subjects: Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - genetics; Cell differentiation; Cell Line, Tumor; Cell proliferation; Cell Proliferation - physiology; Esophageal cancer; Esophageal Neoplasms - genetics; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - metabolism; Esophageal Squamous Cell Carcinoma - pathology; Esophagus; Gene expression; Humans; Immunohistochemistry; Medical prognosis; Medicine; Medicine & Public Health; N-Acetylgalactosaminyltransferases - biosynthesis; N-Acetylgalactosaminyltransferases - genetics; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - metabolism; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Oncology; Patients; Polymerase chain reaction; Prognosis; Risk factors; siRNA; Squamous cell carcinoma; Surgery; Surgical Oncology; Translational Research and Biomarkers
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-020-08431-8

Background β-1,4- N -Acetyl-galactosaminyltransferase 4 (B4GALNT4), an enzyme involved in ganglioside synthesis, is upregulated in many cancers. We examine B4GALNT4 expression and its relationship to prognosis in esophageal squamous cell carcinoma (ESCC). Patients and Methods Expression of B4GALNT4 mRNA and B4GALNT4 protein was analyzed by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively, in 17 human ESCC cell lines and/or clinical specimens from two independent cohorts of 147 and 159 ESCC patients. The contributions of B4GALNT4 to proliferation, invasion, migration, and adhesion was evaluated in ESCC cells subjected to siRNA-mediated gene knockdown. Correlations between clinicopathological parameters and B4GALNT4 expression in clinical specimens were analyzed in both patient cohorts. Results B4GALNT4 mRNA expression levels varied widely in ESCC cell lines, regardless of differentiation status or the originating tissue. Knockdown of B4GALNT4 significantly suppressed the proliferation, invasion, migration, and adhesion of ESCC cell lines compared with control cells. B4GALNT4 mRNA was overexpressed in ESCC tissues compared with adjacent normal esophageal tissues. High mRNA expression was significantly associated with poor disease-free survival and hematogenous recurrence, and high B4GALNT4 protein expression was also significantly related to poor disease-specific survival. On multivariable analysis, high B4GALNT4 expression was an independent predictor of poor prognosis. In both patient cohorts, high B4GALNT4 expression did not correlate with known prognostic factors, such as disease stage, lymphovascular invasion, or squamous cell-carcinoma-related antigen level. Conclusions B4GALNT4 influences the malignant behavior of ESCC cells. B4GALNT4 expression may serve as a novel prognostic marker, independent of established risk factors, for ESCC patients.